Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study of the Efficacy and Safety of DCF Regimen Combined With Camrelizumab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma(ESCC)

NCT05050760 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT05050760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05050760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study of the Efficacy and Safety of DCF Regimen Combined With Camrelizumab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma(ESCC)
Lead sponsor
Xijing Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
September 1, 2021
Completion date
December 31, 2023
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

escc